--- title: "Eloxx Pharmaceuticals (ELOX) news: going concern and offering" url: "https://aibio.space/companies/eloxx-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ELOX going concern and offering news: Eloxx Pharmaceuticals lacks funds for auditor review, expects $0.6 million cash. Eloxx Pharmaceuticals, Inc." --- ELOX Eloxx Pharmaceuticals, Inc. NASDAQ · United States # Eloxx Pharmaceuticals (ELOX) news ELOX going concern and offering news Listings · 2026-08-11 ## [Eloxx reports second-quarter results after a $66.0 million offering and Nasdaq uplisting](https://aibio.space/news/eloxx-reports-second-quarter-results-after-66-0-million-offering/) The company said its June offering and move to the Nasdaq Capital Market strengthened its balance sheet. Cash of $62.0 million is expected to fund operations into mid-2028. ## Latest Eloxx Pharmaceuticals news 1. 2025-08-14 Distress [Eloxx Pharmaceuticals lacks funds for auditor review, expects $0.6 million cash](https://aibio.space/news/eloxx-pharmaceuticals-lacks-funds-auditor-review-expects-0-6-million/) The company also has not filed its annual reports for 2023 and 2024. It expects to disclose substantial doubt about its ability to continue as a going concern. 2. 2025-05-15 Distress [Eloxx Pharmaceuticals files NT 10-Q, cites lack of funds for accountant review](https://aibio.space/news/eloxx-pharmaceuticals-files-nt-10-q-cites-lack-funds-accountant-review/) Eloxx says it cannot afford to engage its auditor to review first quarter 2025 financials, and it expects to disclose substantial doubt about its ability to continue as a going concern. It expects cash of $0.4 million at March 31, 2025. 3. 2025-04-01 Distress [Eloxx Pharmaceuticals files NT 10-K, cannot fund audit and expects going concern doubt](https://aibio.space/news/eloxx-pharmaceuticals-files-nt-10-k-cannot-fund-audit-expects-going/) The late filing covers the year ended December 31, 2024. Eloxx expects cash and cash equivalents of $0.1 million at year end and lists four periodic reports it has not filed. ## Eloxx Pharmaceuticals at a glance - **Ticker**: ELOX - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $62.0 million ### Related companies - [Neurogene](https://aibio.space/companies/neurogene/) NASDAQ: NGNE - [Cel-Sci](https://aibio.space/companies/cel-sci/) AMEX: CVM - [Exicure](https://aibio.space/companies/exicure/) NASDAQ: XCUR - [Nkarta](https://aibio.space/companies/nkarta/) NASDAQ: NKTX - [Carisma Therapeutics](https://aibio.space/companies/carisma-therapeutics/) OTC: CARM - [Hemab Therapeutics Holdings](https://aibio.space/companies/hemab-therapeutics/) NASDAQ: COAG - [Bright Minds Biosciences](https://aibio.space/companies/bright-minds-biosciences/) CSE: DRUG - [Invivyd](https://aibio.space/companies/invivyd/) NASDAQ: IVVD ### Also on NASDAQ - [Erasca](https://aibio.space/companies/erasca/) ERAS - [Oncolytics Biotech](https://aibio.space/companies/oncolytics-biotech/) ONCY - [Fennec Pharmaceuticals](https://aibio.space/companies/fennec-pharmaceuticals/) FENC - [REGENXBIO](https://aibio.space/companies/regenxbio/) RGNX - [LENZ Therapeutics](https://aibio.space/companies/lenz-therapeutics/) LENZ - [HARVARD BIOSCIENCE INC](https://aibio.space/companies/harvard-bioscience/) HBIO ## Eloxx Pharmaceuticals annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$0](https://www.sec.gov/Archives/edgar/data/1035354/000119312526108687/) | [$6.4 million](https://www.sec.gov/Archives/edgar/data/1035354/000119312526108687/) | | Net income (loss) | [-$6.0 million](https://www.sec.gov/Archives/edgar/data/1035354/000119312526108687/) | [-$3.1 million](https://www.sec.gov/Archives/edgar/data/1035354/000119312526108687/) | | Cash from operations | [-$6.3 million](https://www.sec.gov/Archives/edgar/data/1035354/000119312526108687/) | [-$4.7 million](https://www.sec.gov/Archives/edgar/data/1035354/000119312526108687/) | | Cash and equivalents | [$4.8 million](https://www.sec.gov/Archives/edgar/data/1035354/000119312526344964/) | [$111,000](https://www.sec.gov/Archives/edgar/data/1035354/000119312526108687/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $62.0 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Eloxx Pharmaceuticals Has Eloxx Pharmaceuticals issued a going-concern warning? Our latest story on this, dated Aug 14, 2025: "Eloxx Pharmaceuticals lacks funds for auditor review, expects $0.6 million cash". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/eloxx-pharmaceuticals-lacks-funds-auditor-review-expects-0-6-million/). Has Eloxx Pharmaceuticals raised money recently? Our latest story on this, dated Aug 11, 2026: "Eloxx reports second-quarter results after a $66.0 million offering and Nasdaq uplisting". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/eloxx-reports-second-quarter-results-after-66-0-million-offering/). What is the ticker symbol of Eloxx Pharmaceuticals? Eloxx Pharmaceuticals, Inc. trades under the ticker ELOX on NASDAQ. Where is Eloxx Pharmaceuticals listed? Eloxx Pharmaceuticals, Inc. is listed on NASDAQ. What is the SEC CIK of Eloxx Pharmaceuticals? The SEC Central Index Key (CIK) for Eloxx Pharmaceuticals, Inc. is 1035354. Its filings are on SEC EDGAR. How many shares does Eloxx Pharmaceuticals have outstanding? 4,036,459 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-11. Which country or territory is Eloxx Pharmaceuticals listed under? Our directory records Eloxx Pharmaceuticals, Inc. under United States. What does Eloxx Pharmaceuticals do? Our directory classifies Eloxx Pharmaceuticals, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Eloxx Pharmaceuticals? The ISIN recorded for Eloxx Pharmaceuticals, Inc. is US29014R3012. Does aibio.space cover Eloxx Pharmaceuticals? aibio.space lists Eloxx Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Eloxx Pharmaceuticals incorporated? SEC records list its state or country of incorporation as DE. What was Eloxx Pharmaceuticals's revenue last year? $0 for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Eloxx Pharmaceuticals profitable? Eloxx Pharmaceuticals, Inc. reported a net loss of $6.0 million for the fiscal year ended Dec 31, 2025, and used $6.3 million of cash in operations, per its annual report to the SEC. How much cash does Eloxx Pharmaceuticals have? $62.0 million in cash at Jun 30, 2026, per its 10-Q. What is the latest Eloxx Pharmaceuticals (ELOX) stock news? Our latest story on Eloxx Pharmaceuticals, dated Aug 11, 2026: "Eloxx reports second-quarter results after a $66.0 million offering and Nasdaq uplisting". The company said its June offering and move to the Nasdaq Capital Market strengthened its balance sheet. Cash of $62.0 million is expected to fund operations into mid-2028. [Source](https://aibio.space/news/eloxx-reports-second-quarter-results-after-66-0-million-offering/). ## Investor discussion: Eloxx Pharmaceuticals Members talk about Eloxx Pharmaceuticals (ELOX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Eloxx Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-09-11 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1035354/000119312526389422/d152186ds1.htm) 2. 2026-06-01 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,3.03,5.02,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1035354/000119312526249692/d261568d8k.htm) 3. 2026-05-07 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1035354/000119312526212324/d35071ds1.htm) 4. 2026-05-01 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1035354/000119312526201408/d151139d8k.htm) 5. 2025-08-14 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1035354/000110465925078543/tm2523390d1_nt10q.htm) 6. 2025-05-15 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1035354/000110465925049378/tm2515283d1_nt10q.htm) 7. 2025-04-01 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1035354/000110465925030543/tm2511064d1_nt10k.htm) 8. 2024-11-19 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1035354/000110465924120555/tm2428895d1_nt10q.htm) ## Press releases Headlines of Eloxx Pharmaceuticals's own announcements, newest first. Each opens the full release on the newswire that carried it. 1. 2026-10-29 PR Newswire [Eloxx Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Exaluren in Nonsense-Mutation ADPKD](https://www.prnewswire.com/news-releases/eloxx-pharmaceuticals-announces-fda-clearance-of-investigational-new-drug-application-for-exaluren-in-nonsense-mutation-adpkd-302922973.html) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ELOX on TradingView](https://www.tradingview.com/symbols/NASDAQ-ELOX/). ## SEC filings and registration - **SEC name**: Eloxx Pharmaceuticals, Inc. - **CIK**: 1035354 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: ELOX (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: P.O. BOX 274, ARLINGTON, MA, 02476 - **Phone**: 781-577-5300 - **Shares outstanding**: 4,036,459 as of 2026-08-07 (10-Q filed 2026-08-11) - **Former names**: Sevion Therapeutics, Inc.; SENESCO TECHNOLOGIES INC; NAVA LEISURE USA INC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1035354/000119312526428116/d462611d8k.htm) filed 2026-10-22 - [S-1](https://www.sec.gov/Archives/edgar/data/1035354/000119312526389422/d152186ds1.htm) filed 2026-09-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1035354/000119312526345032/d167833d8k.htm) filed 2026-08-11 - [10-Q](https://www.sec.gov/Archives/edgar/data/1035354/000119312526344964/elox-20260630.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1035354/000119312526249692/d261568d8k.htm) filed 2026-06-01 - [S-1](https://www.sec.gov/Archives/edgar/data/1035354/000119312526212324/d35071ds1.htm) filed 2026-05-07 - [10-Q](https://www.sec.gov/Archives/edgar/data/1035354/000119312526204722/elox-20260331.htm) filed 2026-05-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1035354/000119312526201408/d151139d8k.htm) filed 2026-05-01 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001035354), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Eloxx Pharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ELOX, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Eloxx Pharmaceuticals, Inc. - **Ticker**: ELOX - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US29014R3012 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ELOX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/eloxx-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Eloxx Pharmaceuticals (ELOX) news: going concern and offering", 2026-10-31, https://aibio.space/companies/eloxx-pharmaceuticals/